戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 Remodeling During Entresto Therapy for Heart Failure).
2  (<1%) patient in the placebo group (hepatic failure).
3  ameliorate metabolic dysregulation in heart failure.
4 tions of potential drought-induced hydraulic failure.
5  trials for cardiovascular disease and heart failure.
6 tional changes in the heart leading to heart failure.
7 of SDOH in an underserved patient with heart failure.
8  performance and, all too often, spectacular failure.
9  arrhythmogenesis and progression into heart failure.
10 ulmonary vascular resistance and right heart failure.
11 underlie the many different causes of kidney failure.
12 eting cell swelling-induced microcirculatory failure.
13 of ureteral obstruction with eventual kidney failure.
14 s has never been investigated in human heart failure.
15 - and hospital-level factors associated with failure.
16  with survivors at risk for subsequent heart failure.
17 re regulation and reducing the risk of heart failure.
18  mainly contributed to determine a treatment failure.
19 or early toxicity-related death or treatment failure.
20 pattern of occurrence in patients with heart failure.
21 tes and the leading cause of end-stage renal failure.
22 gain better insight into the causes of graft failure.
23 e self-care behaviour in patients with heart failure.
24 d with acute myocardial infarction and heart failure.
25 with excess morbidity and mortality in heart failure.
26  and 15,614 individuals with nonimmune renal failure.
27 intravascular cocaine results in acute heart failure.
28 logic cure and 204 experienced microbiologic failure.
29 immune suppression, and sepsis-related organ failure.
30 ntify the risk factors associated with graft failure.
31 f KEs as a treatment for patients with heart failure.
32 k and may aggravate shock severity and organ failure.
33 haracterized by sepsis and acute respiratory failure.
34 d renal outcomes with empagliflozin in heart failure.
35 ents and not applicable in those with kidney failure.
36 ress, may contribute to pancreatic beta-cell failure.
37 nterstitial pneumonia and severe respiratory failure.
38  patients who had Covid-19 without end-organ failure.
39  via endotracheal tube for acute respiratory failure.
40 4.1% on anticoagulants, and 14.7% with renal failure.
41  cells associated with reduced risk of graft failure.
42 ation with the aim of preventing respiratory failure.
43  disorder characterized by progressive renal failure.
44 -1.3 medications (P = 0.52) in eyes with SLT failure.
45  retrocorneal membranes at the time of graft failure.
46 testinal pathogens and the risk of treatment failures.
47 aintain the information flow under node/link failures.
48 equired in this area to avoid future control failures.
49 ive targets accounting for over 50% of these failures(1-3).
50 rillation, 1.75 (95% CI 1.56-1.97) for heart failure, 1.76 (95% CI 1.51-2.05) for acute myocardial in
51 ion after MI (7% versus 12%), previous heart failure (10% versus 19%), atrial fibrillation (6% versus
52 arge to hospice (37.2% vs 25.3%), extubation failure (12.3% vs 6.1%), tracheostomy (21.6% vs 4.5%), d
53                             Moreover, 29 (27 failure, 2 warning) of 60 patients who were positive for
54 ficant difference in the incidence of kidney failure (31.7% with intervention vs 27.3% with placebo;
55 sis (Non-ACLF) and in acute-on-chronic liver failure (ACLF) by CCT and ROTEM including agreement of b
56  predict survival and acute-on-chronic liver failure (ACLF) in patients awaiting LT, as well as early
57 gression of acute and acute-on-chronic liver failure (ACLF).
58 = 104, 35.6%) related to sepsis, respiratory failure, acute respiratory distress syndrome, or multipl
59                    Acute decompensated heart failure (ADHF) is a highly morbid condition among adults
60 s hospitalized for acute decompensated heart failure (ADHF) was well-tolerated and led to improved ou
61 n, and the end points of mortality and heart failure admissions in the CASTLE-AF study (Catheter Abla
62 afts were lost due to patient death or graft failure after >25 years.
63 d poor process stability, leading to reactor failure after 40 days.
64 it represents the major cause of acute liver failure (ALF) requiring liver transplantation in USA and
65           Three re-DMEK eyes developed graft failure, all achieving final BCVA <=0.30 logMAR (Snellen
66 us albus) to MeHg also caused early breeding failure and a ~20% reduction in breeding numbers at envi
67 pical cardiovascular diagnoses such as heart failure and acute myocardial infarction, need frequently
68                  Participants with virologic failure and anticipated antiretroviral susceptibility re
69  Exercise intolerance, associated with heart failure and death in general populations, is not well st
70 nary vasculature that results in right heart failure and death, are usually assessed with invasive pr
71 ith azoxymethane (AOM) to induce acute liver failure and HE.
72 he molecular mechanisms of age-related heart failure and highlight exercise as a valuable experimenta
73                                  Endothelial failure and immunological graft rejection remain long-te
74 ment of volume status in patients with heart failure and may represent a mechanism contributing to th
75 les cases, associated with secondary vaccine failure and modified clinical illness, is emerging in Vi
76  COVID-19 are common and contribute to organ failure and mortality.
77 ermine whether BDG was associated with organ failure and patient mortality, while accounting for the
78 differentiation is associated with treatment failure and poor outcome in metastatic castration-resist
79  cardiovascular death in patients with heart failure and reduced ejection fraction (HFrEF).
80 emias and a significant reason for treatment failure and relapse.
81 ecreases over time, which leads to treatment failure and symptom recurrence.
82 ulant phenotype) could predict midterm graft failure and to investigate potential functional role of
83 years, during which 287 death-censored graft failures and 424 deaths occurred.
84 to differentiate reinfections from treatment failures and to identify transmission linkages and assoc
85  the 3,478 participants progressed to kidney failure, and 803 died.
86 l control with dose-escalated RT, pattern of failure, and adverse effects.
87  protein levels, such as hypertension, heart failure, and anxiety.
88                   Cardiac arrhythmias, heart failure, and nonfatal coronary syndromes are also common
89 ovascular death, rehospitalization for heart failure, and pacemaker implantation after a TAVR procedu
90 ing data on clinical management, respiratory failure, and patient mortality.
91 nt inflammation, history of previous implant failures, and pain/discomfort at the implant site were s
92 s by Glasgow Coma Scale and Sequential Organ Failure Assessment, and central circadian rhythm by mela
93  After adjusting on age and Sequential Organ Failure Assessment, serum CXCL10/IP-10 (P = 0.047) and G
94 me a therapeutic target for preventing heart failure-associated ventricular arrhythmia.
95 ientific cooperation of members of the Heart Failure Association of the ESC, the Heart Failure Societ
96                                     Definite failure at 1 year was 13.6% in the preimplementation gro
97 f chronic dialysis treatment, and with organ failure at ICU admission.
98 the ICRS, that is, correlated to an anatomic failure at the site of implantation in an advanced disea
99  in treatment time, satisfaction and risk of failure between O and S.
100           Secondary endpoints were treatment failure (biopsy-proven acute rejection, graft loss, or d
101                                  Bone marrow failure (BMF) in Fanconi anemia (FA) patients results fr
102 literature on the causes of kidney allograft failure, both early and late, both nonimmune and alloimm
103 ne follow-up after hospitalization for heart failure can increase 7-day follow-up and reduce in-perso
104 pair pathways in human cells, how DNA repair failures can lead to human disease, and how PARP inhibit
105 (73.0% versus 78.7%), acute noncardiac organ failure, cardiac arrest (34.3% versus 35.7%), and receiv
106 osteoporosis, non-AIDS cancer, chronic renal failure, cardiovascular and cerebrovascular disease, obe
107 ctor for the progression to end-stage kidney failure, cardiovascular morbidity, and premature death.
108 ial immunosuppression regimens and allograft failure cause significant morbidity and mortality.
109                                Antipsychotic failure coincided with reduced dopamine neuron firing, w
110  increased risk of developing incident heart failure compared to a subject at the 10th percentile in
111 ortality are at a higher risk for transplant failure compared with patients with the same duration of
112 available data sets of human and mouse heart failure, demonstrated that EPRS acted as an integrated n
113 vided excellent predictability in extubation failure detection in critically ill patients.
114 urgery can mitigate the progression to heart failure, disability, and death.
115 ernal causes at the nodal level and external failures due to an adverse environment, and develop a pa
116                                  We consider failures due to internal causes at the nodal level and e
117            The primary outcome was treatment failure during the 3-day course of amoxicillin or placeb
118 P in Patients Stabilized From an Acute Heart Failure Episode), the in-hospital initiation of sacubitr
119 iarrhea and often followed by multiple organ failure, especially of the respiratory and cardiovascula
120 l remodeling ( EF >5% and ESV 10%) and heart failure event/cardiovascular death.
121 GLT2 inhibition on fatal and non-fatal heart failure events and renal outcomes in all randomly assign
122 e, 14.8-33.4) months, 52 deaths and 24 heart failure events occurred.
123 ve Remote Monitoring for Prediction of Heart Failure Exacerbation) examined the performance of a pers
124 sis remains poor as many patients with heart failure experience symptoms that negatively impact Quali
125 saving for patients with advanced intestinal failure experiencing complications of parenteral nutriti
126 se of explantation was functional refractive failure followed by spontaneous extrusion of the ICRS, t
127 nonadherence as the major cause of virologic failure for 9 (45%) of 20 highly treatment-experienced p
128       The basis of fluoroquinolone treatment failure for Mycoplasma genitalium is poorly understood.
129 e remains the most common cause of treatment failure for patients with acute myeloid leukemia (AML) w
130 ith a significant increase in reported heart failure from 1.64% (95% CI 0.82-2.65) to 11.72% (3.00-24
131 olled during hospitalisation for acute heart failure from 358 centres in 44 countries on six continen
132 ce of Proteobacteria in the congestive heart failure group (p = 0.014), particularly due to an increa
133 RT-experienced Ugandan adults with virologic failure (&gt;=1000 copies/mL) using leftover plasma after v
134                                        Heart failure has previously been linked to sleep disorders th
135 isk of ESKD, with the highest risk for heart failure (hazard ratio, 11.40; 95% confidence interval, 8
136 are to a large cohort of patients with heart failure, heart transplantation, and left ventricular ass
137 CI, 1.28-2.09, P value = 8.07 x 10-5), heart failure (HF) (OR = 1.61, 95% CI, 1.32-1.95, P value = 1.
138 h New York Heart Association Class III heart failure (HF) and a prior HF hospitalization (HFH) within
139 nsated hypertrophy (CH) until signs of heart failure (HF) are apparent using a trans-aortic pressure
140                                        Heart failure (HF) is a major source of morbidity and mortalit
141  leading cause of death and morbidity, heart failure (HF) is responsible for a large portion of healt
142 al Mitral Regurgitation), treatment of heart failure (HF) patients with moderate-severe or severe sec
143 or determinant of clinical outcomes in heart failure (HF) patients.
144 been implicated in the pathogenesis of heart failure (HF) with preserved ejection fraction (HFpEF).
145                                        Heart failure (HF), the leading cause of death in developed co
146                              217 total heart failure hospitalisations occurred in the ferric carboxym
147 porter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in pati
148 nsporter-2 (SGLT-2) inhibitors reduced heart failure hospitalization and end-stage renal disease.
149 es and presented an increased risk for heart failure hospitalization that warrants further study.
150 ent MI or coronary revascularization), heart failure hospitalization, and all-cause mortality (Medica
151 n for a combined end point (events) of heart failure hospitalizations and cardiovascular death.
152 agliflozin reduced the total number of heart failure hospitalizations that required intensive care (H
153 shown to contribute to HE during acute liver failure; however, TGFbeta1 must be activated to bind its
154 eriencing HP had a marginally higher risk of failure (HR = 1.16, 95% CI = 0.6-2.1), but this relation
155 ve in both prevention and treatment of heart failure in 2 preclinical animal models.
156 ion was observed in 7 cases and annuloplasty failure in 5.
157  patients who had Covid-19 without end-organ failure in a 1:1 ratio to receive either LY-CoV555 or ma
158 tive stress, in mediating RV hypertrophy and failure in congenital heart disease is unknown.
159 eutic in acute hyperinflammatory respiratory failure in COVID-19 patients.
160 ) would serve as a predictive tool for graft failure in patients (n = 181) who received a kidney tran
161 ong-term complications leading to late graft failure in penetrating keratoplasty (PK).
162 imens, and portends high rates of first-line failure in sub Saharan Africa.
163 e management acute or acute on chronic liver failure in the ICU, related to five groups (cardiovascul
164 , often resulting in hematopoietic stem cell failure in the most severe cases.
165  proposes a novel nonlinear model of cascade failure in weighted complex networks considering overloa
166 yopathies, which are a common cause of heart failure in young people, have increased during the last
167 nts with hippocampus lesions suffer profound failures in episodic memory.
168 rceived by many to be expensive and prone to failure, in part explaining its low rates of implementat
169 between brain structure and markers of heart failure including ejection fraction and NT-proBNP.
170 to target macrophage metabolism during heart failure, including antidiabetic therapies, anti-inflamma
171  Factors that predicted death-censored graft failure independent of both donor and recipient clinical
172                                        Heart failure, induced via myocardial infarction, causes a dec
173                                  CD4+ T cell failure is a hallmark of chronic hepatitis C virus (HCV)
174  during sympathetic activation, and in heart failure is a major determinant of cardiac physiology and
175                                        Heart failure is a major public health problem affecting over
176                                        Heart failure is a prominent complication of type 2 diabetes m
177            Switching therapy for virological failure is relatively rare at this time, and the recomme
178 lity of human organs for patients with organ failure-is limited by molecular incompatibilities betwee
179 the OptiLink HF trial (Optimization of Heart Failure Management Using OptiVol(TM) Fluid Status Monito
180 and myocardial infarction (MI)-induced heart failure mouse models.
181 sepsis, pneumonia, pneumothorax, respiratory failure, myocardial infarction, thyrotoxicosis, alcohol,
182                     Ten trials were of heart failure (n = 4068 patients), 11 of mixed disease (n = 81
183 nsfer, and frequently defines the success or failure of a transformation.
184 le dopamine D2 receptor (D2R) levels and the failure of antipsychotic drugs to rescue adult behaviora
185  preclinical models of HCC with the clinical failure of AR antagonists in patients with advanced HCC
186 ver, the molecular mechanisms underlying the failure of beta-cells to respond to glucose in T2D remai
187                                              Failure of CF closure results in colobomas.
188 , rebleeding from both adhesive and cohesive failure of clots decreases survival from hemorrhage in v
189 at may be simultaneously responsible for the failure of immuno-surveillance.
190 ppointing in treating UTI, likely due to the failure of infused antibiotics to penetrate the bladder
191 haracterized by insulin resistance with late failure of insulin production, severe hyperglycemia/diab
192 or to treatment is associated with long-term failure of integrase inhibitor-containing first-line reg
193 y significantly contribute to the success or failure of MSC-based virotherapy as well as generate new
194  severe congenital malformations caused by a failure of neural tube closure during early embryonic de
195    These findings may explain the persistent failure of NK cell therapy in patients with solid tumors
196 l subcellular mechanism for the maturational failure of oligodendrocytes and offers a potential thera
197 ls between humans and mice, and explains the failure of potent biotin biosynthesis inhibitors in stan
198        Recent studies have revealed that the failure of proteostasis with age is triggered by develop
199 s in a deterioration of these functions, and failure of RA signaling is perhaps associated with norma
200 apilla morphology could be a risk factor for failure of selective biliary cannulation (SBC) and post
201                                              Failure of SLT was defined as any further glaucoma proce
202                             Furthermore, the failure of TERT promoter mutations to consistently corre
203                               The cumulative failure of the AADI was defined as intraocular pressure
204                            He attributes the failure of the Multiple Risk Factor Intervention Trial t
205 ariant, showing that the change results in a failure of the polymerisation of alpha/beta/gamma lamini
206 t health and scientific investigation is the failure of these cells to achieve full functional maturi
207      Chick cardiac crest ablation results in failure of this septation, phenocopying the human heart
208 s bacteriocin limitations, the successes and failures of this technology thus far, the challenges tha
209                                           At failure onset, it may be difficult to forecast the final
210 ned risk of death, hospitalization for heart failure or an emergent/urgent heart failure visit requir
211 eased mortality vulnerability, but hydraulic failure or biotic attack may dominate the process during
212 older, presented with acute congestive heart failure or non-ST-segment-elevation myocardial infarctio
213  95% CI, 1.1-3.7; P = 0.04), and respiratory failure (OR, 4.7; 95% CI, 1.1-26.3; P = 0.049).
214 contributing to the superior long-term heart failure outcomes observed with these agents.
215 er of patients with MI develop chronic heart failure over time.
216 the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) t
217 the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation),
218 educed ammonia concentrations in acute liver failure patients.
219  Ablation for Atrial Fibrillation With Heart Failure) population.
220               During the pandemic, the heart failure program at New York-Presbyterian Hospital in New
221 he endoplasmic reticulum (ER) is complex and failure-prone.
222             The diabetic, hypertensive heart failure rat (mRen27/tetO-shIR) were treated with empagli
223  during long-term follow-up with a low graft failure rate: 5% class 1, vs 30% class 2, vs 50% class 3
224                                          The failure rates of SBC with Type 3 papilla and Type 4 papi
225  The 6-month and 12-month freedom from local failure rates were 97.0% and 88.2%.
226 red to generate evidence about UAS lifespan, failure rates, and performance under different weather c
227 veloping the outcomes of mortality and heart failure remained similar across years, although the diff
228                    Acute decompensated heart failure remains the most common cause of hospitalization
229                 Vein graft disease (VGD) and failure result from complex pathophysiological processes
230                        We assess the cardiac failure risk in patients receiving osimertinib by evalua
231 ficiency virus (HIV) imparts increased heart failure risk to women.
232 rt study, prediction models of acute ovarian failure risk were developed using eligible female US and
233                            Right ventricular failure (RVF) is a cause of major morbidity and mortalit
234  pneumonia; and O: the CLIF consortium organ failure score (CLIF-C OFs).
235  Meta-Analysis Global Group in Chronic Heart Failure score, genotype, level of BB exposure, and BB pr
236 l cell count (ECC), rates of secondary graft failure (SGF), and postoperative complications.
237 tory stridor and acute hypoxemic respiratory failure shortly after the stent was placed.
238 rt Failure Association of the ESC, the Heart Failure Society of America and the Japanese Heart Failur
239 re Society of America and the Japanese Heart Failure Society.
240  was associated with a similar risk of graft failure (subdistribution hazard ratio [sHR] 0.74; 95% co
241 renal and liver injury or/and multiple organ failure, suggesting a spread of the SARS-CoV-2 in blood.
242 f (1) death; (2) rehospitalization for heart failure symptoms and valve prosthesis complication; or (
243 nd is a constitutional inherited bone marrow failure syndrome.
244 her rates of hospitalization for acute heart failure than other race/ethnic groups.
245                 Main outcomes were treatment failure (the proportion of women in which surgery failed
246                                    For heart failure, the pooled proportion, based on 38 studies (n=5
247 risingly, the simultaneous loss of RAP80 and failure therein of BRCA1 PARsylation results in the dysr
248 elomere biology genes leading to bone-marrow failure, these data provide evidence that genetically in
249 rategy to prevent the irreversible pulmonary failure threatening the life of COVID-19 patients.
250 ss of human beta-cell maturity and beta-cell failure through activation of the BMP/SMAD signaling pat
251 s pathological cardiac hypertrophy and heart failure through persistent activation of mTOR.
252 of TAVR versus SAVR durability in which TAVR failure times were varied to determine the impact of TAV
253                                              Failure to achieve kidney recovery after immune checkpoi
254 ciated with each hour until antibiotics, and failure to control for large potential confounders inclu
255                                          The failure to cure rate after salvage surgery was 27.6% in
256 er patients (52%) developed refractory heart failure to disabling New York Heart Association function
257 phorylation of the SAF-A DNA-binding domain; failure to execute this pathway leads to accumulation of
258 rgued that psychosis may emerge because of a failure to learn sensory statistics, resulting in an imp
259  this study were to: (1) measure the rate of failure to provide defect-free postoperative venous thro
260 ) chemoprophylaxis, (2) identify reasons for failure to provide defect-free VTE chemoprophylaxis, and
261 ic derangement, and human factors, including failure to recognize and reluctance to manage the failed
262  this review, we discuss the consequences of failure to reprogram histone methylation during three cr
263 stent and accurate dose monitoring; however, failure to return one or both badges, reversal of badges
264                      The primary outcome was failure to spontaneously pass the gestational sac within
265 tematic processes in formulating guidelines, failure to state conflicts of interest, and lack of cons
266 plants, soft sensors could expose faults and failures to the operator.
267  distinct types of errors: failures-to-stop, failures-to-go, and incorrect choices.
268 were predictive of distinct types of errors: failures-to-stop, failures-to-go, and incorrect choices.
269 -HF (Baroreflex Activation Therapy for Heart Failure) trial was a multicenter, prospective, randomize
270 , every 4 weeks group) confirmed virological failures (two sequential measures >=200 copies per mL).
271  daily plus corticosteroids, until treatment failure, unacceptable toxicity, or death.
272 TAVR, and disease symptoms (congestive heart failure, unstable angina, non-ST-elevation myocardial in
273 or heart failure or an emergent/urgent heart failure visit requiring intravenous treatment (415 versu
274 scular death or hospital admission for heart failure was 0.38 (95% CI 0.30-0.47).
275                                    Treatment failure was defined as (1) any further surgical procedur
276                                      Vaccine failure was defined as TBE despite adherence to the reco
277 l infarction, or rehospitalization for heart failure was not different between the 2 groups (odds rat
278            No sex difference in time to task failure was observed in either trial.
279                                 Time to task failure was significantly shorter after sleep deprivatio
280 hyroidism, multiglandular disease, and renal failure were excluded.
281 re recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin
282                                        These failures were largely due to a lack of MMP-selective age
283 secutive anaesthetic weans (23 successes, 24 failures) were identified from a single-centre cohort of
284      Engineered genetic systems are prone to failure when their genetic parts contain repetitive sequ
285  preexisting LA-DRVs and risk of virological failure whereas 14/25 (56.0%) did not.
286 mes of fluid removal in patients with kidney failure who are treated with intermittent haemodialysis,
287 e able to identify those patients with heart failure who have a cardio-inflammatory phenotype and wil
288  read depth (n = 3), or quality control (QC) failure with an external RNA control (n = 1).
289 yocardial infarction, because of respiratory failure with hypoxia and hemodynamic instability in crit
290 cardiac inflammation in a rat model of heart failure with preserved ejection fraction (HFpEF).
291 re at high risk for the development of heart failure with preserved ejection fraction (HFpEF).
292 related with NAFLD among patients with heart failure with preserved ejection fraction (HFpEF).
293                          Patients with heart failure with reduced ejection fraction (HFrEF; heart fai
294  cohort of Medicare beneficiaries with heart failure with reduced ejection fraction and existing qual
295  to patients without diabetes who have heart failure with reduced ejection fraction.
296 with reduced ejection fraction (HFrEF; heart failure with reduced left ventricular ejection fraction
297 ession showed increasing odds of respiratory failure with sC5b-9 (odds ratio 31.9, 95% CI 1.4 to 746,
298 on abnormalities, hemorrhage, and multiorgan failure with up to 33% case fatality rates (CFRs).
299 utcomes, including hospitalization for heart failure, with this benefit extending to patients without
300 otransmitter GABA is essential, and reuptake failure worsens human seizures.

 
Page Top